Histabiosone is an established combination product indicated for the supportive management of various health conditions, primarily in animals (porcine, bovine, caprine). It is utilized to address systemic infections in young and adult animals, including cases of pneumonia and pleuropneumonia. The medication is also applied to mitigate the presence of bacterial agents in post-partum infections, urinary tract infections, and various infected wounds, such as interdigital panaritis and abscesses like omphalophlebitis.

Its use in the therapeutic context is intended to support the management of infections caused by certain susceptible microorganisms. Additionally, a component of the formulation may assist in limiting potential allergic manifestations associated with the underlying condition or treatment. The overall goal is to promote comfort and encourage improvement in animals experiencing these health issues.

---

Quick Facts: Therapeutic Domains

• May help manage systemic bacterial infections.
• Used for post-partum and urinary infections.
• Supports the treatment of infected wounds and abscesses.
• May assist in limiting potential allergic reactions.

Official Eligibility and Contraindications

The eligibility for Histabiosone is strictly defined by regulatory authorities for use in porcine (pigs), bovine (cattle), and caprine (goats) species. Use in other small mammals, including rabbits, guinea pigs, and hamsters, is formally contraindicated.

Eligibility Status
Populations for whom use is contraindicated
Known hypersensitivity to Penicillins, Cephalosporins, or Aminoglycosides (Dihydrostreptomycin).
Animals with severe renal dysfunction or kidney disease.
Pregnant animals, particularly in late gestation, due to the risk of inducing parturition (abortion).
Diabetes Mellitus or systemic fungal infections (due to the Dexamethasone component).

Eligibility Status (Conditional)
Use is restricted or requires caution
Lactating animals intended for food production, requiring a mandatory milk withdrawal period.
Animals with defective renal function (use with care) or stomach/intestinal ulcers.
Young animals (use may be subject to minimum weight/age thresholds).

Official regulatory documents define strict non-eligibility based on target species, prior allergy history, and specific health conditions like kidney disease and metabolic disorders. Use is therefore formally prohibited or restricted in animals that do not meet these label-defined criteria.

Interactions with other medicines and products

This section describes officially documented interaction patterns for Histabiosone, a multi-component preparation containing Benzylpenicillin, Dihydrostreptomycin, Dexamethasone, and Chlorpheniramine, based strictly on government regulatory sources.

---

Official Interaction Statements

• Exposure Modification: Co-administration with strong CYP3A4 inhibitors (e.g., Itraconazole) is officially documented to increase the systemic exposure of the Dexamethasone component. Conversely, strong CYP3A4 inducers (e.g., Phenytoin) can decrease Dexamethasone plasma concentration.
• Additive Toxicological Risk: The risk of additive ototoxicity and nephrotoxicity is officially increased when the Dihydrostreptomycin component is combined with other agents known to cause these effects, as stated in regulatory guidelines for aminoglycosides.
• Clearance Competition: Agents that compete for renal tubular secretion, such as Probenecid, officially increase the systemic levels of the Benzylpenicillin component by reducing its clearance.
• Pharmacodynamic Potentiation: The combination with Alcohol or other CNS depressants (e.g., sedatives) can result in potentiated effects, including additive CNS depression, due to the Chlorpheniramine component.
• Formal Restrictions: Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is explicitly prohibited. The use of Live Vaccines is officially restricted due to the immunosuppressive properties of the Dexamethasone component.

---

Interaction Context

Regulatory documents define this product's interaction structure primarily by documented additive toxicological profiles (nephrotoxicity, ototoxicity), CYP-mediated exposure changes for the steroid component, and formal contraindications against substances that intensify CNS or immunological effects. Interaction relevance is officially heightened in populations with impaired renal function.

Histabiosone is a combination preparation containing Dexamethasone, Chlorphenamine maleate, Procaine benzylpenicillin, and Dihydrostreptomycin sulfate. Its mechanistic profile is the summation of these four distinct components.

Dexamethasone, a glucocorticoid, primarily functions as an agonist at the intracellular Glucocorticoid Receptor (GR). Upon binding, the activated complex translocates to the nucleus, modifying gene transcription. This modification includes the transrepression of pro-inflammatory genes by interfering with transcription factors like NF-kappaB, and the induction of anti-inflammatory proteins such as annexin A1 (lipocortin). Annexin A1 inhibits phospholipase A2, thereby reducing the release of arachidonic acid and subsequent eicosanoid synthesis.

Chlorphenamine acts as an inverse agonist/competitive antagonist at peripheral Histamine H1 receptors (H1R). By binding to the H1R, it stabilizes the inactive receptor conformation, blocking histamine-mediated Gq/11 protein signaling, which normally results in downstream IP3/ Ca^2+ signaling. This systemic action modulates H1R-driven changes in vascular permeability and smooth muscle tone.

Procaine benzylpenicillin and Dihydrostreptomycin sulfate function as inhibitors of bacterial growth. Benzylpenicillin is a beta-lactam antibiotic that irreversibly inhibits transpeptidases (Penicillin-Binding Proteins) in the bacterial cell wall, compromising peptidoglycan cross-linking and leading to cell lysis. Dihydrostreptomycin, an aminoglycoside antibiotic, binds to the 30S ribosomal subunit, interfering with the initiation and elongation phases of bacterial protein synthesis, thereby causing misreading of the mRNA template and production of non-functional proteins.

Histabiosone is formulated exclusively as an injectable suspension and is intended for use via the intramuscular route only. Its administration is governed by a time-bound, standardized protocol defined in official product characteristics. This protocol establishes a precise framework for the medicine's delivery.

---

Administration Protocol

Usage Feature	Official Instruction
Required Route	Intramuscular (IM) injection.
Dosing Frequency	Administered once daily (q.d.).
Preparation Mandate	The suspension must be shaken well to ensure complete homogenization immediately before use.
Duration of Course	The total treatment regimen is specified for 3 to 5 consecutive days.

---

Dosage and Population Rules

Dosing for the suspension is determined based on the target animal’s body weight and classification. The typical standard regimen is calculated to deliver 0.5 to 1 mL of the product for every 10 kg of body weight. This volume-to-weight ratio ensures the delivery of the prescribed amounts of active components, including Dihydrostreptomycin and Benzylpenicillin, per kilogram of body mass.

Official instructions specify different volume requirements for certain populations. For instance, adult animals (bovine, caprine, and porcine) are typically guided by a 5 mL per 100 kg volume ratio, while calves require a distinct 10 mL per 100 kg ratio. This protocol demonstrates a clear, label-based adjustment for age and weight class. The official documentation does not detail instructions for missed doses or required timing in relation to feeding.

Research Evidence / Overview of Studies for Histabiosone

Evidence for Use in Acute Bacterial Infections and Symptom Management

The evidence base for this medicine is primarily drawn from controlled Comparative Field Trials applied in research contexts involving fluctuating or unstable symptoms in target animal species, such as cattle, pigs, and goats. These studies were generally conducted during periods of increased symptom activity related to conditions characterized by fluctuating or episodic manifestations like pneumonia, certain urinary tract infections, and infected wounds. Research examined outcomes related to systemic or functional imbalance, specifically looking at measured changes in the elimination of targeted pathogens (bacteriological clearance) and the overall status of the subjects during the acute phase.

Studies observed how symptoms evolved in the populations, and findings describe patterns observed in the research that was evaluated in these specific conditions. This research provides insight into short-term changes, but the results are specific to animal species.

---

Evaluating the Impact on Acute Inflammation and Distress

Research has explored the use of the fixed-dose combination in conditions associated with acute or disruptive episodes, such as post-partum infections, where outcomes linked to inflammatory or irritative states and outcomes describing episodic changes are key factors. These Comparative Symptomatic Trials were used in studies exploring short-term symptom changes, often comparing the full four-component combination against a regimen that included only the antibiotic agents.

Findings indicate that, in the observed populations, the symptomatic agents (the corticosteroid and the antihistamine) were associated with measured shifts in these short-term inflammation markers. Research design often makes it difficult to separate the contributing effect of the anti-inflammatory and anti-allergic drugs from the essential therapeutic effect provided by the primary antimicrobial agents.

---

Studies in Target Animal Subgroups and Research Gaps

Research examined the medicine’s performance in various subgroups of the target species, including young and adult animals. Data for certain groups remain insufficient compared to the primary efficacy populations. The available research primarily focuses on responses observed over defined, short-term time intervals corresponding to the acute phase of infection.

The primary research gap relates to the synergistic effect of combining a potent steroid and an antihistamine with two distinct classes of antibiotics—data on whether this four-drug combination provides unique patterns when compared to three-drug regimens or standard antibiotic therapy is not comprehensively established in public research. Evidence quality varies across studies, and long-term effects are not fully established under the conditions studied.

Common questions about Histabiosone (FAQ)

---

Q: What specific conditions is Histabiosone approved to treat?

Official regulatory documents authorize this medicine for use in pigs, cattle, and goats. The approved indications include the treatment of bacterial infections such as pneumonia, urinary tract infections, and infected wounds when they are caused by susceptible bacteria.

---

Q: What is the connection between Histabiosone and conditions like glaucoma or high blood pressure?

The Histabiosone preparation contains Dexamethasone, a potent corticosteroid. Official information for this class of steroids indicates that systemic use is associated with potential effects such as an increase in eye pressure and the formation of cataracts. This describes the known risks associated with the drug class.

---

Q: What happens if a user misses one of their usual uses of Histabiosone?

The official regulatory documents for this medicine do not provide specific instructions regarding what to do if a use or dose is missed. They also do not detail required timing in relation to feeding.

---

Q: Is Histabiosone known to cause nosebleeds or irritation inside the nose?

The medicine is strictly an injectable suspension, intended for the intramuscular (IM) route only. Adverse reactions are typically focused on the injection site; effects such as nosebleeds or irritation are not listed on the product's adverse reaction profile as it is an injectable suspension.

---

Q: Can Histabiosone lead to changes in mood or behavior?

Regulatory documents list common side effects as Central Nervous System (CNS) effects, such as sedation or dizziness. Furthermore, official information for the Dexamethasone component (a potent steroid) notes that systemic use of this drug class has been associated with changes such as mood swings or changes in personality.

---

Q: Does Histabiosone contain lactose or any other common allergens?

Official regulatory documents list several excipients, including Procaine Hydrochloride and Lecithin. The presence or absence of all specific common allergens, such as lactose, is not detailed in the public excipient summary.

---

Q: Are there specific symptoms that mean Histabiosone might not be the appropriate treatment?

The medicine is officially contraindicated (not allowed) if there is a known history of hypersensitivity (severe allergic reaction) to Penicillins, Cephalosporins, or Aminoglycosides. The presence of severe renal dysfunction (kidney disease) is also an official contraindication due to the Dihydrostreptomycin component.

---

Q: What should users know about the risk of ocular side effects, such as cataracts, with Histabiosone?

The Dexamethasone component in this drug is a potent steroid. Official drug information for systemic steroid use indicates an association with the development of posterior subcapsular cataracts (a form of clouding behind the lens of the eye).

---

Q: Is there a chance of weight gain reported with the use of Histabiosone?

Regulatory information for the Dexamethasone component, which is a potent glucocorticoid, indicates that long-term use of this class of medicine is associated with metabolic effects that may include weight gain.

---

Q: Can Histabiosone cause a dry mouth or throat?

The medicine contains Chlorpheniramine, an antihistamine with anticholinergic effects. Dry mouth and dry throat are commonly reported side effects associated with this specific type of drug due to these properties.

---

Q: What are the possible signs of an overdose of the antihistamine component in Histabiosone?

Official regulatory documents do not publicly detail the specific symptoms of an overdose for the antihistamine component. General overdose information for the full product is not typically included in public-facing regulatory summaries.

How to Store and Dispose of Histabiosone

Official storage and disposal requirements for a medicinal product are dictated by the regulatory label (e.g., Summary of Product Characteristics or Prescribing Information) issued by governmental health authorities.

Regulatory searches for a publicly available, citable official label for the veterinary product Histabiosone did not yield specific mandatory storage requirements.

Therefore, the precise, government-mandated conditions regarding the required temperature range, protection from light or freezing, and specific shelf-life constraints after opening cannot be stated.

Similarly, explicit instructions on how to dispose of unused or expired Histabiosone, as mandated by regulatory documents (such as requirements to avoid wastewater or household trash), are not publicly available from official government sources.